Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease

Hiddo J. Lambers Heerspink, Toshiharu Ninomiya, Vlado Perkovic, Mark Woodward, Sophia Zoungas, Alan Cass, Mark Cooper, Diederick E. Grobbee, Giuseppe Mancia, Carl Eric Mogensen, Bruce Neal, John Chalmers

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

AimsIndividuals with diabetes and chronic kidney disease (CKD) are at high risk for cardiovascular disease. In these analyses of the ADVANCE trial, we assessed the effects of a fixed combination of perindopril-indapamide on renal and cardiovascular outcomes in patients with type 2 diabetes according to baseline CKD stage. Methods and resultsPatients with type 2 diabetes were randomized to perindopril-indapamide (4 mg/1.25 mg) or placebo. Treatment effects on cardiovascular (cardiovascular death, myocardial infarction, or stroke) and renal outcomes were compared in subgroups defined by baseline Kidney Disease Outcome Quality Initiative CKD stage. Homogeneity in treatment effect was tested by adding interaction terms to the relevant Cox models. The study included 10 640 participants with known CKD status, of whom 6125 did not have CKD, 2482 were classified as CKD stage 1 or 2, and 2033 as CKD stage ≥3. The relative treatment effects on major cardiovascular events were similar across all stages of CKD, with no heterogeneity in the magnitude of the effects for any outcome. In contrast, the absolute treatment effects approximately doubled in those with CKD stage ≥3 when compared to those with no CKD. For every 1000 patients with CKD stage ≥3 treated for 5 years, active treatment prevented 12 cardiovascular events when compared with six events per 1000 patients with no CKD. ConclusionThe treatment benefits of a routine administration of a fixed combination of perindopril-indapamide to patients with type 2 diabetes on cardiovascular and renal outcomes, and death, are consistent across all stages of CKD at baseline. Absolute risk reductions are larger in patients with CKD highlighting the importance of blood pressure-lowering in this population.

Original languageEnglish
Pages (from-to)2888-2896
Number of pages9
JournalEuropean Heart Journal
Volume31
Issue number23
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Indapamide
Perindopril
Chronic Renal Insufficiency
Type 2 Diabetes Mellitus
Kidney
Therapeutics
Numbers Needed To Treat
Kidney Diseases

Keywords

  • ACE-inhibitor
  • chronic kidney disease
  • type 2 diabetes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Lambers Heerspink, H. J., Ninomiya, T., Perkovic, V., Woodward, M., Zoungas, S., Cass, A., ... Chalmers, J. (2010). Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal, 31(23), 2888-2896. https://doi.org/10.1093/eurheartj/ehq139

Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. / Lambers Heerspink, Hiddo J.; Ninomiya, Toshiharu; Perkovic, Vlado; Woodward, Mark; Zoungas, Sophia; Cass, Alan; Cooper, Mark; Grobbee, Diederick E.; Mancia, Giuseppe; Mogensen, Carl Eric; Neal, Bruce; Chalmers, John.

In: European Heart Journal, Vol. 31, No. 23, 12.2010, p. 2888-2896.

Research output: Contribution to journalArticle

Lambers Heerspink, HJ, Ninomiya, T, Perkovic, V, Woodward, M, Zoungas, S, Cass, A, Cooper, M, Grobbee, DE, Mancia, G, Mogensen, CE, Neal, B & Chalmers, J 2010, 'Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease', European Heart Journal, vol. 31, no. 23, pp. 2888-2896. https://doi.org/10.1093/eurheartj/ehq139
Lambers Heerspink, Hiddo J. ; Ninomiya, Toshiharu ; Perkovic, Vlado ; Woodward, Mark ; Zoungas, Sophia ; Cass, Alan ; Cooper, Mark ; Grobbee, Diederick E. ; Mancia, Giuseppe ; Mogensen, Carl Eric ; Neal, Bruce ; Chalmers, John. / Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. In: European Heart Journal. 2010 ; Vol. 31, No. 23. pp. 2888-2896.
@article{1130ec8ece734632956cbd719bccf4dd,
title = "Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease",
abstract = "AimsIndividuals with diabetes and chronic kidney disease (CKD) are at high risk for cardiovascular disease. In these analyses of the ADVANCE trial, we assessed the effects of a fixed combination of perindopril-indapamide on renal and cardiovascular outcomes in patients with type 2 diabetes according to baseline CKD stage. Methods and resultsPatients with type 2 diabetes were randomized to perindopril-indapamide (4 mg/1.25 mg) or placebo. Treatment effects on cardiovascular (cardiovascular death, myocardial infarction, or stroke) and renal outcomes were compared in subgroups defined by baseline Kidney Disease Outcome Quality Initiative CKD stage. Homogeneity in treatment effect was tested by adding interaction terms to the relevant Cox models. The study included 10 640 participants with known CKD status, of whom 6125 did not have CKD, 2482 were classified as CKD stage 1 or 2, and 2033 as CKD stage ≥3. The relative treatment effects on major cardiovascular events were similar across all stages of CKD, with no heterogeneity in the magnitude of the effects for any outcome. In contrast, the absolute treatment effects approximately doubled in those with CKD stage ≥3 when compared to those with no CKD. For every 1000 patients with CKD stage ≥3 treated for 5 years, active treatment prevented 12 cardiovascular events when compared with six events per 1000 patients with no CKD. ConclusionThe treatment benefits of a routine administration of a fixed combination of perindopril-indapamide to patients with type 2 diabetes on cardiovascular and renal outcomes, and death, are consistent across all stages of CKD at baseline. Absolute risk reductions are larger in patients with CKD highlighting the importance of blood pressure-lowering in this population.",
keywords = "ACE-inhibitor, chronic kidney disease, type 2 diabetes",
author = "{Lambers Heerspink}, {Hiddo J.} and Toshiharu Ninomiya and Vlado Perkovic and Mark Woodward and Sophia Zoungas and Alan Cass and Mark Cooper and Grobbee, {Diederick E.} and Giuseppe Mancia and Mogensen, {Carl Eric} and Bruce Neal and John Chalmers",
year = "2010",
month = "12",
doi = "10.1093/eurheartj/ehq139",
language = "English",
volume = "31",
pages = "2888--2896",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "23",

}

TY - JOUR

T1 - Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease

AU - Lambers Heerspink, Hiddo J.

AU - Ninomiya, Toshiharu

AU - Perkovic, Vlado

AU - Woodward, Mark

AU - Zoungas, Sophia

AU - Cass, Alan

AU - Cooper, Mark

AU - Grobbee, Diederick E.

AU - Mancia, Giuseppe

AU - Mogensen, Carl Eric

AU - Neal, Bruce

AU - Chalmers, John

PY - 2010/12

Y1 - 2010/12

N2 - AimsIndividuals with diabetes and chronic kidney disease (CKD) are at high risk for cardiovascular disease. In these analyses of the ADVANCE trial, we assessed the effects of a fixed combination of perindopril-indapamide on renal and cardiovascular outcomes in patients with type 2 diabetes according to baseline CKD stage. Methods and resultsPatients with type 2 diabetes were randomized to perindopril-indapamide (4 mg/1.25 mg) or placebo. Treatment effects on cardiovascular (cardiovascular death, myocardial infarction, or stroke) and renal outcomes were compared in subgroups defined by baseline Kidney Disease Outcome Quality Initiative CKD stage. Homogeneity in treatment effect was tested by adding interaction terms to the relevant Cox models. The study included 10 640 participants with known CKD status, of whom 6125 did not have CKD, 2482 were classified as CKD stage 1 or 2, and 2033 as CKD stage ≥3. The relative treatment effects on major cardiovascular events were similar across all stages of CKD, with no heterogeneity in the magnitude of the effects for any outcome. In contrast, the absolute treatment effects approximately doubled in those with CKD stage ≥3 when compared to those with no CKD. For every 1000 patients with CKD stage ≥3 treated for 5 years, active treatment prevented 12 cardiovascular events when compared with six events per 1000 patients with no CKD. ConclusionThe treatment benefits of a routine administration of a fixed combination of perindopril-indapamide to patients with type 2 diabetes on cardiovascular and renal outcomes, and death, are consistent across all stages of CKD at baseline. Absolute risk reductions are larger in patients with CKD highlighting the importance of blood pressure-lowering in this population.

AB - AimsIndividuals with diabetes and chronic kidney disease (CKD) are at high risk for cardiovascular disease. In these analyses of the ADVANCE trial, we assessed the effects of a fixed combination of perindopril-indapamide on renal and cardiovascular outcomes in patients with type 2 diabetes according to baseline CKD stage. Methods and resultsPatients with type 2 diabetes were randomized to perindopril-indapamide (4 mg/1.25 mg) or placebo. Treatment effects on cardiovascular (cardiovascular death, myocardial infarction, or stroke) and renal outcomes were compared in subgroups defined by baseline Kidney Disease Outcome Quality Initiative CKD stage. Homogeneity in treatment effect was tested by adding interaction terms to the relevant Cox models. The study included 10 640 participants with known CKD status, of whom 6125 did not have CKD, 2482 were classified as CKD stage 1 or 2, and 2033 as CKD stage ≥3. The relative treatment effects on major cardiovascular events were similar across all stages of CKD, with no heterogeneity in the magnitude of the effects for any outcome. In contrast, the absolute treatment effects approximately doubled in those with CKD stage ≥3 when compared to those with no CKD. For every 1000 patients with CKD stage ≥3 treated for 5 years, active treatment prevented 12 cardiovascular events when compared with six events per 1000 patients with no CKD. ConclusionThe treatment benefits of a routine administration of a fixed combination of perindopril-indapamide to patients with type 2 diabetes on cardiovascular and renal outcomes, and death, are consistent across all stages of CKD at baseline. Absolute risk reductions are larger in patients with CKD highlighting the importance of blood pressure-lowering in this population.

KW - ACE-inhibitor

KW - chronic kidney disease

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=78649875453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649875453&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehq139

DO - 10.1093/eurheartj/ehq139

M3 - Article

C2 - 20501479

AN - SCOPUS:78649875453

VL - 31

SP - 2888

EP - 2896

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 23

ER -